Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$90.07 0.80 (0.88%) as of 4:30 Thu 4/18


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.97(B)
Last Volume: 944,850 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 658,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $62,013,572
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 58
End Date 2024-01-18 2023-10-17 2023-04-18 2022-04-18

   
Records found: 1355
  Page 2 of 55  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-03-03 4 A $0.00 $0 D/D 10,500 79,278     -
   Lapalme Pierre Director   –       •      –    2015-03-03 4 S $106.57 $2,131,400 D/D (20,000) 30,150     -
   Lapalme Pierre Director   –       •      –    2015-03-03 4 OE $11.15 $284,800 D/D 20,000 50,150     -
   Mueller Brian VP, Corporate Controller   •       –      –    2015-03-03 4 S $109.46 $766,210 D/D (7,000) 8,800     -
   Mueller Brian VP, Corporate Controller   •       –      –    2015-03-03 4 OE $28.23 $197,610 D/D 7,000 15,800     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-03 4 AS $107.42 $537,097 D/D (5,000) 215,157     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-03-02 4 S $107.00 $1,658,500 D/D (15,500) 68,676     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-03-02 4 OE $39.06 $605,430 D/D 15,500 84,176     -
   Davis George Eric SVP, General Counsel   •       –      –    2015-03-02 4 S $108.31 $2,491,027 D/D (23,000) 64,246     -
   Davis George Eric SVP, General Counsel   •       –      –    2015-03-02 4 OE $26.49 $609,270 D/D 23,000 87,246     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-02 4 AS $108.44 $542,195 D/D (5,000) 220,157     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-02 4 AS $107.96 $323,893 I/I (3,000) 43,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-02 4 OE $12.99 $38,970 I/I 3,000 46,195     -
   Davis George Eric SVP, General Counsel   •       –      –    2015-01-16 5 GD $0.00 $0 D/D 75 66,081     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-01-09 4 AS $94.14 $188,286 D/D (2,000) 225,157     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-24 4 AS $88.73 $177,462 D/D (2,000) 227,157     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-24 4 AS $88.73 $266,193 I/I (3,000) 43,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-24 4 OE $12.99 $38,970 I/I 3,000 46,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-10 4 AS $95.00 $190,000 I/I (2,000) 43,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-10 4 OE $12.99 $25,980 I/I 2,000 45,195     -
   Lewis Alan Director   –       •      –    2014-12-04 4 S $89.90 $674,225 D/D (7,500) 21,400     -
   Lewis Alan Director   –       •      –    2014-12-04 4 OE $21.51 $161,325 D/D 7,500 28,900     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-12-03 4 S $91.01 $1,092,161 D/D (12,000) 31,590     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-12-03 4 OE $38.59 $463,080 D/D 12,000 43,590     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-02 4 S $91.82 $459,100 D/D (5,000) 4,593     -
  1355 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 55
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us